116 related articles for article (PubMed ID: 19414838)
1. Molecular markers and death from prostate cancer.
Concato J; Jain D; Uchio E; Risch H; Li WW; Wells CK
Ann Intern Med; 2009 May; 150(9):595-603. PubMed ID: 19414838
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers and mortality in prostate cancer.
Concato J; Jain D; Li WW; Risch HA; Uchio EM; Wells CK
BJU Int; 2007 Dec; 100(6):1259-63. PubMed ID: 17850375
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density.
Calvocoressi L; Uchio E; Ko J; Radhakrishnan K; Aslan M; Concato J
J Investig Med; 2018 Dec; 66(8):1142-1146. PubMed ID: 30297390
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
5. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
6. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
7. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
8. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
9. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
10. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
11. Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study.
Skriver C; Dehlendorff C; Borre M; Brasso K; Larsen SB; Dalton SO; Nørgaard M; Pottegård A; Hallas J; Sørensen HT; Friis S
Ann Intern Med; 2019 Apr; 170(7):443-452. PubMed ID: 30831581
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.
Mucci LA; Powolny A; Giovannucci E; Liao Z; Kenfield SA; Shen R; Stampfer MJ; Clinton SK
J Clin Oncol; 2009 Nov; 27(33):5627-33. PubMed ID: 19858401
[TBL] [Abstract][Full Text] [Related]
13. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.
Chamie K; DeVere White RW; Lee D; Ok JH; Ellison LM
Cancer; 2008 Nov; 113(9):2464-70. PubMed ID: 18666213
[TBL] [Abstract][Full Text] [Related]
14. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
Ritter MA
Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
[TBL] [Abstract][Full Text] [Related]
15. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
Patel AA; Chen MH; Renshaw AA; D'Amico AV
JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
[TBL] [Abstract][Full Text] [Related]
16. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
17. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
19. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
20. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]